Neuroendocrine Tumor

P3, N=427, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027

We found several risk factors (age, non-white race, female sex, non-tobacco user, lack of H. pylori) to be associated with AIG. The risk of gastric malignancy was elevated in AIG compared to NAIG which already is a precancerous condition. Early identification of AIG is important for cancer screening.

While further validation is needed, our findings indicate that multifocal SI-NETs consist of spatially distinct tumor cell subtypes affected by local cellular interactions, providing insight into SI-NET intra-tumoral heterogeneity, possible microenvironmental-triggered tumorigenesis, and potential subtype-targeted therapeutic strategies.

Clinical outcome was favorable, with complete recovery of motor deficits following functional rehabilitation. Radiological follow-up at one year post-radiotherapy showed no signs of recurrence.

P1, N=15, Recruiting, Emory University | Not yet recruiting --> Recruiting | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2025 --> Sep 2026

The auto-segmentation model correctly identified tumor regions, and the radiomics model accurately predicted grade; new associations between genomic and radiomic features were identified. This automated pipeline can incorporate a radiomics model into preoperative PNET decision-making.

A personalized, multidisciplinary approach is essential for maximizing PRRT's benefits in NET management. This review article summarizes current evidence and describes patient specific circumstances, enabling treating provider to make informed PRRT sequencing decisions.

A patient with a history of a parathyroid adenoma, papillary thyroid carcinoma, and acoustic neuroma was suspected of harboring a NET based upon 2 circulating tumor nucleic acid tests that used different methodology and a positive 68gallium-dodecanetetraacetic acid-tyrosine-3-octreotate (68Ga-DOTATATE) scan corresponding to a 2.2-cm right gluteal mass, which was found to be an intramuscular hemangioma expressing somatostatin receptor 2 subtype (SSTR2) in the endothelial cells. Hemangiomas are among the most frequently reported lesions mimicking a NET and should be considered when somatostatin receptor scanning localizes an isolated lesion in an unusual anatomic area.

This report describes the first adolescent case of EAS due to a neuroendocrine tumor within a sacrococcygeal teratoma. Complementary PET/CT on FDG metabolism and SSTR expression is critical for localizing occult neuroendocrine components. Complete tumor resection and multidisciplinary collaboration are key to favorable outcomes, expanding the spectrum of pediatric EAS and providing valuable insight into its evaluation and management.

P=N/A, N=2000, Recruiting, Changhai Hospital

PRRT combined with everolimus-based immunosuppression has demonstrated controllable safety and preliminary antitumor activity in patients with relapsed NETLM after LT who have been strictly screened, but myelosuppression requires close monitoring and timely symptomatic treatment.

This case underscores the importance of considering MEN1 even in elderly patients with atypical manifestations, emphasizes the value of integrating prior medical history into diagnosis, and suggests a potential role of rs2959656 in MEN1 pathogenesis.